Fujifilm Sonosite has received the US Food and Drug Administration’s (FDA) 510(k) and CE mark approval in Europe for its new mountable ultrasound system, SonoSite SII.
The new ultrasound system can be used in regional anesthesia, vascular access and trauma applications.
SonoSite SII is a portable system that can be used across multiple hospital environments, including a zero footprint option for space-constrained rooms.
The system features a new touchscreen user interface with a clinician-driven menu logic, which adaptively adjusts to the use case.
It also includes an embedded dual transducer, which enables quick switching between transducers with two simple taps of the screen.
In addition, the SII features DirectClear technology that advances transducer performance by increasing penetration and contrast resolution.
Fujifilm Sonosite global direct sales vice president Brian Leck said: "SonoSite introduced the first mountable ultrasound system in 2007, providing an unparalleled solution for clinicians who valued and needed to accelerate their clinical workflow.
"The new SII ultrasound system expands on the design goals of our mountable legacy system by offering more functionality, and an even better user experience from start to finish."
In January, the company also obtained (FDA) 510(k) and CE mark approval for its new portable ultrasound system, SonoSite Edge II.
Featuring advanced DirectClear technology, the new portable ultrasound system has been developed to be used in emergency medicine and critical care applications.
Image: Fujifilm Sonosite has launched new new mountable ultrasound system SonoSite SII. Photo: courtesy of Business Wire / FUJIFILM SonoSite, Inc.